Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation

Part of paid clinical trials in Ann Arbor, Michigan.

Sponsor
University of Michigan
Study ID
NCT07642908
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory tests, and questionnaires. The aims of this study are to compare brain chemicals in LRRK2 PD patients with iPD patients and to correlate brain chemicals with motor and cognitive tests in LRRK2 PD and iPD patients.

Key Dates

Start date
Sep 18, 2025
Status verified
Jun 2026
Primary completion
Sep 17, 2026
Completion
Sep 17, 2026

Study Design

Enrollment
15 participants (estimated)

Arms

  • Arm: LRRK2
    Individuals with PD and LRRK2 genetic mutation.
  • Arm: iPD
    Individuals with PD and without LRRK2 genetic mutation (Pre-existing cohorts, not recruiting).

Primary Outcome Measure

Cholinergic Differences Between leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease (PD) and Idiopathic/non-LRRK2 PD (iPD) [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of MichiganAnn ArborMichigan48106
Nathan Alexander, BSc
[email protected]
734-998-6894
Gerianne Que, BSc
[email protected]
734-998-4790
Prabesh Kanel, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Ann Arbor, MI

By condition
Parkinson's disease
By specialty
NeurologyBrain disorders
By research site
University of Michigan· Ann Arbor, MI

Related Studies